Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Open | $76.48 |
Close | - |
Volume / Avg. | 831.92K / 1.12M |
Day Range | 75.58 - 79.38 |
52 Wk Range | 45.50 - 84.89 |
Market Cap | $8.07B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 64 |
Short Interest | 4.5% |
Days to Cover | 1.39 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ:ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
There is no analysis for Intra-Cellular Therapies.
Intra-Cellular Therapies has a consensus price target of $88.69.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $78.785 last updated Today at July 23, 2024 at 3:51 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q2 earnings are confirmed for Monday, August 5, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.